Eyevensys, a developer of gene therapies for ophthalmic diseases, announced today that it raised $12 million in a Series B plus funding round.
The funding, led by Korea Investment Partners, also includes existing investors who will join the round and will support the accelerated development of Eyevensys’ EYS809 program for treating wet age-related macular degeneration (AMD) and the advancement of its EYS611 program targeting geographic atrophy (GA) and retinitis pigmentosa.
Get the full story at our sister site, Drug Delivery Business News.